A type 2 diabetes treatment has been found to also have ‘off-label’ benefits for glucose control in the liver and in fatty cells known as adipose. The study shows that exenatide, a treatment that targets the pancreas to improve glucose absorption, enhances glucose uptake and reduces insulin resistance in the liver and in adipose tissue.